Bioatla

BCAB · NASDAQ

$1.33+$0.02 (+1.53%)TodayMarket closed · Oct 20, 3:56 PM ET

Prev close $1.31

Latest news

NewsAug 21, 5:06 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsAug 11, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Press releaseMay 18, 6:45 AM ETGlobe Newswire
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
NewsApr 15, 5:05 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsApr 1, 1:06 PM ET
12 Health Care Stocks Moving In Wednesday's Intraday Session
NewsApr 1, 8:05 AM ET
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
NewsMar 31, 5:05 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseMar 31, 4:06 PM ETGlobe Newswire
BioAtla Announces Share Consolidation
Press releaseMar 31, 4:05 PM ETGlobe Newswire
BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
NewsMar 10, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMar 2, 12:05 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
Press releaseMar 2, 7:30 AM ETGlobe Newswire
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
NewsFeb 27, 4:05 PM ET
12 Health Care Stocks Moving In Friday's After-Market Session
NewsFeb 27, 7:05 AM ET
12 Health Care Stocks Moving In Friday's Pre-Market Session
NewsFeb 19, 4:06 PM ET
12 Health Care Stocks Moving In Thursday's After-Market Session
NewsJan 5, 4:27 AM ETAvi Kapoor
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Press releaseDec 31, 7:00 AM ETGlobe Newswire
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
Press releaseNov 21, 12:25 AM ETGlobe Newswire
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
NewsNov 18, 4:06 PM ET
12 Health Care Stocks Moving In Tuesday's After-Market Session
Press releaseNov 13, 4:05 PM ETGlobe Newswire
BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
NewsNov 12, 11:03 AM ET
What's Next: BioAtla's Earnings Preview
Press releaseNov 7, 9:00 AM ETGlobe Newswire
BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas
Press releaseNov 5, 8:00 AM ETGlobe Newswire
BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025
Press releaseOct 23, 8:00 AM ETGlobe Newswire
BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society
Press releaseOct 20, 8:00 AM ETGlobe Newswire
BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025
Press releaseAug 4, 8:00 AM ETGlobe Newswire
BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025
NewsMay 21, 5:06 PM ET
12 Health Care Stocks Moving In Wednesday's After-Market Session
NewsMay 5, 4:02 PM ET
A Preview Of BioAtla's Earnings
Press releaseApr 29, 8:00 AM ETGlobe Newswire
BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
NewsMar 26, 2:02 PM ET
Earnings Outlook For BioAtla
Press releaseMar 19, 8:00 AM ETGlobe Newswire
BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025
Press releaseNov 7, 4:01 PM ETGlobe Newswire
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress
Press releaseOct 31, 8:00 AM ETGlobe Newswire
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024
NewsOct 9, 8:12 AM ETKaustubh Bagalkote
'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months
Press releaseAug 1, 8:00 AM ETGlobe Newswire
BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

12 Health Care Stocks Moving In Wednesday's After-Market Session

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

12 Health Care Stocks Moving In Tuesday's After-Market Session

BioAtla Announces Share Consolidation

BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

12 Health Care Stocks Moving In Monday's Intraday Session

BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's After-Market Session

Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)

BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

12 Health Care Stocks Moving In Tuesday's After-Market Session

BioAtla Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

What's Next: BioAtla's Earnings Preview

BioAtla's Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

BioAtla to Announce Second Quarter 2025 Financial Results and Provide Business Highlights on August 7, 2025

12 Health Care Stocks Moving In Wednesday's After-Market Session

A Preview Of BioAtla's Earnings

BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025

Earnings Outlook For BioAtla

BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months

BioAtla to Announce Second Quarter 2024 Financial Results and Provide Business Highlights on August 8, 2024